Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing

SOURCE: Elegen News

May 14, 2024

Elegen announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines; John Ballantyne, co-founder of Aldevron; and existing investors.